Navigation Links
Merge Technologies Receives Expected Additional NASDAQ Notification
Date:11/16/2007

ults contemplated by such forward-looking statements, including, but not limited to: the restatement may take longer to complete than expected; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; risks and effects of the past and current restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; costs, risks and effects of legal proceedings and investigations, including the formal investigation being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; the uncertainty created by and the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company's senior management; and other risk factors detailed in the Company's filings with the Securities and Exchange Commission.

You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. We do not have, or undertake any obligation to, publicly update, revise or correct any of the forward-looking statements after the date of this announcement, or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise. This announcement should be read in conjunction with the risk factors, financial information and other information contained in the filings that the Company makes and previously has made with the Securities and Exchange Commission.


'/>"/>
SOURCE Merge Technologies Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Climatic variations influence the emergence of cholera in Africa
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
5. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
6. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
7. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
8. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
9. GSI Securitization Completes Merger and Domicile Transfer
10. Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...t therapy given during surgery extends survival ti...fe expectancy in non-small cell lung cancer (NSCLC...e is very hard to treat, especially when it has sp...ors at Thomas Jefferson University Hospital, Phila...
...rson aged 40 or over has a lifetime risk of heart ...ave high blood pressure. Heart failure is an incre...ed by increasing pressure within the heart which m...body. Typical symptoms are breathlessness and fati...
...prescribed medicines by the doctor are to be verif...ay an important role in helping you. Experts at th...t of your health care team, alongside your physici... your medications dispensed at the once pharmacy. ...
... coughs are harmless, while others merit medical a..., symptom. Most often it's part and parcel of a co...o spread the infection, there's little you can do....a more serious underlying medical condition. Doct...
Other Medicine News:
(Date:8/18/2008)... JERUSALEM, Israel, August 18 /PRNewswire-FirstCal...) ( http://www.oramed.com ), a developer,of oral d..., entitled "Open,Label Study to Assess the Safety,...f Five Oral Insulin Formulations in Healthy,Subjec...ing 44th Annual,Meeting of the European Associatio...
(Date:8/18/2008)...Industry Leader with Strong Clinical Research Rela...owth Organizations to Lead Commercialization, SAN...- NewCardio, Inc.,(OTC Bulletin Board: NWCI) a ca...nced that Vincent W. Renz has joined NewCardio as ... commercialization effort, to include,business dev...
(Date:8/18/2008)... BETHESDA, Md., Aug. 18 /- ...al company developing novel, proprietary,antibodie...toimmune,diseases, will host a webcast and confere... 10:00 a.m. Eastern Time (4:00 p.m. Central Europe...e published in the Journal,SCIENCE on August 15, 2...
(Date:8/15/2008)... AUDUBON, Pa., Aug. 15 /- Globus Medi...nt manufacturer in the world, today announced,that...en implanted under an,Investigational Device Exemp...ald Johnson II and Dr. Rhett Murray., The FLEXUS(...tween two,spinous processes with minimal disruptio...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 1Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 4Drinking polyphenol rich Concord grape juice may improve memory in older adults 20857 1Drinking polyphenol rich Concord grape juice may improve memory in older adults 20857 2Louisiana May Mandate Fluoridation Despite Evidence of Harm 20853 1Louisiana May Mandate Fluoridation Despite Evidence of Harm 20853 2Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 1Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 2Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 3Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 4
..., Calif., May 02, 2007 /PRNewswire/ -- Ceregene, I...hase 1 trial of,CERE-110, a gene therapy product d...he treatment of Alzheimer,s disease. After one,yea...ho received,CERE-110 in the trial indicate that a ...rated, and an interim analysis suggested that,the ...
...Y, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data ha...sclerosis (RRMS),patients treated with COPAXONE(R)...munosuppression with mitoxantrone experienced a,90...MRI)-monitored,disease activity compared to their ...d were sustained throughout the 24-month study,per...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: